Abstract
Forty-two patients with chronic renal insufficiency were subjected to Brulamycin therapy to combat complications such as sepsis, infection of the lower respiratory tract (bronchopneumonia) or of the urinary tract, Cimino fistula inflammation or peritonitis when the pathogenic agent was sensitive to nothing but aminoglycosides. The proper Brulamycin dose was selected under close clinical and laboratory control so as to fit the dialysed patient and his state of impaired renal function. The various forms of dialysis have been studied to determine their Brulamycin blood level diminishing effects. Familiarity with these effects is as important as with the patient's age, sex, body weight and actual state of renal function. The results confirm the experience gained by other authors that Brulamycin treatment—in curative non-toxic doses as indicated by the blood level index—is useful against severe infectious complications in anuric patients
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aztreonem: A monocycline beta-lactam antibiotic.Am. J. Med. 78, (2A)1 (1985).
Cojocel, C., Dociu, N., Ceacmacudis, E., Baumann, K.: Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption.Nephron, 37, 113 (1984).
DeBroe, M. E.: Prevention of aminoglycoside nephrotoxicity.Proc. Eur. Dial. Transplant. Assoc., 22, 959 (1985).
Faragó, E., Kiss, J., Gömöry, A., Aranyosi, J., Juhász, I., Mihóczy, L.: Amikacin: in vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results.Int. J. Clin. Pharmacol. Biopharm., 17, 421 (1979).
Faragó, E., Kiss, J., Mihóczy, L.: Data on sisomycin effect: human pharmacokinetic and bacteriological studies.Int. J. Clin. Pharmacol. Ther. Toxicol., 18, 128 (1980).
Gatell, J. M., Zamora, L., Araujo, V.: Prospective controlled comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin. VIIIth Int. Congr. Infect. Parasit. Dis. Stockholm 1982.
Gatell, J. M., SanMiguel, J. G., Zamora, L., Araujo, V., Castells, C., Moreno, A., Jimenez de Anta, M. T., Marin, J. L., Elena, M., Ballesta, A.: Tobramycin and amikacin nephrotoxicity.Nephron, 41, 337 (1985).
Graber, H., Ács, M., Deutsch, I., Ludwig, E., Magyar, T.: Microbiologic, pharmacokinetic and clinical effectiveness of Tobramycin (in Hung.). Orv. Hetil.,121, 213 (1980).
Graber, H.: Antibiotic therapy for internal bacterial diseases (in Hung.). Gyógyszereink,36, 129 (1986).
Golper, T. A., Pulham, J., Bennett, W. M.: Removal of therapeutic drugs by continuous arteriovenous hemofiltration.Arch. Intern. Med., 145, 1651 (1985).
Grove, D. C., Randall, W. A.: Assay methods of antibiotics, a Laboratory manual. Med. Encyclopedia Inc., New York 1955.
Jones, J. V., Parker, W. A., Sketris, I. S.: The effect of plasmapheresis on therapeutic drugs.Dial. Transplant., 14, 225 (1985).
Kluwe, W. M., Hook, J. B.: Analysis of gentamycin uptake by rat cortical slices.Toxicol. Appl. Pharmacol., 45, 531 (1978).
Lesar, T. S., Rotschafer, J. C., Strand, L. M., Solem, L. D., Zaske, D. E.: Gentamycin dosing errors with four commonly used nomograms.JAMA, 248, 1190 (1982).
Lietman, P. S.: A perspective on the future of aminoglycoside. 13th Int. Congr. Chemother. Vienna 1983.
Ludwig, E., Deutsch, I., Székely, É., Csiba, Á., Graber, H.: Dosing of antibiotics by means of personal computer (in Hung.). Gyógyszereink,36, 42 (1986).
Mana, J., Gatell, J. M., Araujo, V., Zamora, L., SanMiguel, J. G.: Aminoglycoside toxicity.Lancet, ii, 13 (1982).
Miskolczi, P., Vereczkey, L.: Medication and problems of dosing for patients with impaired renal function (in Hung.). Gyógyszereink,34, 2 (1984).
Mondorf, A. W., Zegelmann, M., Klose, J., Hendus, J., Breier, J.: Comparative studies on the action of aminoglycoside and cephalosporins on the proximal tubule of the human kidney.J. Antimicrob. Chemother., 4, Suppl. A, 53 (1978).
Moore, R. D., Smith, C. R., Lipsky, J. J., Mellits, E. D., Litman, P. S.: Risk factors for nephrotoxicity in patients treated with aminoglycosides.Ann. Intern. Med., 100, 352 (1984).
Pagliaro, L. A., Benet, L. Z.: Critical complication of terminal half-lives, percent excreted unchanged and changes of half-life in renal and hepatic dysfunction for studies in human with references.J. Pharmacokinet. Biopharm. 3, 33 (1975).
Schentag, J. J., Plaut, M. E.: Patterns of urinary beta-2 microglobulin excretion in patients treated with aminoglycosides.Kidney Int., 17, 654 (1980).
Smith, C. R., Zipsky, J. J., Laskin, O. L., Hollmann, D. B., Mellits, E. D., Longstreth, J., Litman, P. S.: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamycin and tobramycin.N. Engl. J. Med., 302, 110 (1980).
Zaske, D. E., Bootman, J. L., Strate, R. G.: Increased burn patient survival with individualized dosages of gentamycin.Surgery, 91, 142 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lőcsey, L., Faragó, E. & Kakuk, G. Experience with Brulamycin therapy in dialysed patients. International Urology and Nephrology 20, 539–549 (1988). https://doi.org/10.1007/BF02550617
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02550617